Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014037 | 0.85 | EPHX1 (0.54) | EPHX2EPHX1KDM4EALDH1A1 | |
| SCHEMBL4017201 | 0.77 | EPHX2 (0.76) | EPHX2EPHX1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14984060 | 0.73 | EPHX2 (0.76) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL4997641 | 0.71 | EPHX2 (0.73) | EPHX2EPHX1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28045440 | 0.71 | ALOX15 (0.64) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL278101 | 0.71 | L3MBTL3 (0.46) | HPGD | |
| SCHEMBL14072843 | 0.70 | EPHX2 (0.74) | EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL13768765 | 0.70 | EPHX2 (0.72) | EPHX2EPHX1 | |
| SCHEMBL1425023 | 0.69 | EPHX2 (0.74) | EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL5000909 | 0.69 | EPHX2 (0.74) | EPHX2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132176-A1 | 4-PIPERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | claimed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2008112022-A1 | 4 -PI PERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2008112022-A1 | 4 -PI PERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | EPHX1, ECE1, LIPG | EPHX2 5/4885EPHX1 1/4885KDM4E 995/4885 |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885EPHX1 1/4885KDM4E 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.